ストックスクリーナーアプリを入手
3.28
2.96%
-0.10
アフターアワーズ：
3.29
0.01
+0.30%
前日終値:
$3.38
開ける：
$3.3
24時間の取引高:
9,594
Relative Volume:
0.70
時価総額：
$121.20M
収益：
-
当期純損益:
$-25.50M
株価収益率:
-4.2597
EPS:
-0.77
ネットキャッシュフロー:
$-30.10M
1週間 パフォーマンス:
-9.89%
1か月 パフォーマンス:
-19.01%
6か月 パフォーマンス:
+24.71%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$3.1137
$3.40
1週間の範囲:
$3.1137
$3.68
52週間の値動き範囲:
$2.20
$4.48
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
EPRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
3.28 | 121.20M | 0 | -25.50M | -30.10M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-21 | 開始されました | Craig Hallum | Buy |
| 2024-11-14 | 開始されました | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc (EPRX) 最新ニュース
Eupraxia Pharmaceuticals (EPRX) Projected to Post Earnings on Monday - Defense World
When (EPRX) Moves Investors should Listen (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Reports Strong Q4 2024 Results and Operational Progress - MSN
Here's Why We're Watching Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation - Yahoo Finance
Learn to Evaluate (EPRX) using the Charts (EPRX:CA) - Stock Traders Daily
Eupraxia Pharmaceuticals files report with SEC By Investing.com - Investing.com South Africa
Eupraxia Pharmaceuticals files report with SEC - Investing.com India
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results - Weekly Voice
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results -March 20, 2025 at 05:38 pm EDT - MarketScreener
Eupraxia Reports Clinical Win and Stronger Financials: Net Loss Shrinks as Trial Shows Promise - Stock Titan
(EPRX) Equity Market Report (EPRX:CA) - Stock Traders Daily
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 1.7% – What’s Next? - Defense World
(EPRX) Optimized Trading Opportunities (EPRX:CA) - Stock Traders Daily
(EPRX) Proactive Strategies (EPRX:CA) - Stock Traders Daily
How to Take Advantage of moves in (EPRX) (EPRX:CA) - Stock Traders Daily
(EPRX) Daily Stock Insights (EPRX:CA) - Stock Traders Daily
(EPRX) Stock Evaluation Report (EPRX:CA) - Stock Traders Daily
Eupraxia Pharmaceuticals is undervalued, Research Capital says - Cantech Letter
Eupraxia reports progress in EoE drug trial with promising results By Investing.com - Investing.com Canada
Medicenna Therapeutics Corp. - Baystreet.ca
Dye & Durham Limited - Baystreet.ca
Eupraxia Pharmaceuticals Inc. - Baystreet.ca
Eupraxia Pharmaceuticals Shares Rise on Positive Drug Trial Data - MarketWatch
Eupraxia Pharmaceuticals Reports Latest Updates - Investing.com
Eupraxia Pharmaceuticals Reports Latest Updates By Investing.com - Investing.com South Africa
Eupraxia Pharmaceuticals Inc. Announces Additional Positive Clinical Data from its Ongoing RESOLVE Phase 1b/2a Trial Evaluating EP-104GI for Treatment of Eosinophilic Esophagitis - Marketscreener.com
Eupraxia Pharmaceuticals Reports Promising Trial Results for Eosinophilic Esophagitis Treatment - TipRanks
Eupraxia reports progress in EoE drug trial with promising results - Investing.com India
Eupraxia Pharmaceuticals Brief: Announcing "Positive" Data From RESOLVE Phase 1b/2a Trial Of EP-104GI For Treatment Of Eosinophilic Esophagitis - Marketscreener.com
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis - The Globe and Mail
Eupraxia's EoE Drug Achieves 94% Reduction in Key Inflammatory Markers Without Steroid Side Effects - StockTitan
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Research Coverage Started at Craig Hallum - Defense World
Craig-Hallum starts Eupraxia at Buy, sees ‘significant upside’ potential - Yahoo Finance
Craig-Hallum sets $12 target for Eupraxia stock, rates it a Buy - Investing.com Australia
Craig-Hallum sets $12 target for Eupraxia stock, rates it a Buy By Investing.com - Investing.com South Africa
Top Premarket Decliners -February 21, 2025 at 07:50 am EST - Marketscreener.com
Short Interest in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Declines By 6.0% - Defense World
Propel Holdings Inc. - Baystreet.ca
Eupraxia Pharmaceuticals appoints new CFO By Investing.com - Investing.com Nigeria
EPRXEupraxia Pharmac Latest Stock News & Market Updates - Stock Titan
Exco Technologies Limited - Baystreet.ca
Eupraxia Appoints Alex Rothwell To Succeed Bruce Cousins As CFO - Nasdaq
Eupraxia Pharmaceuticals Announces CFO Succession - GuruFocus.com
Eupraxia Pharmaceuticals Announces CFO Succession Amid Strategic Advancements - TipRanks
Eupraxia Pharmaceuticals appoints new CFO - Investing.com
Eupraxia Pharmaceuticals Inc (EPRX) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):